Management of Systemic Steroid in HIV Patient with Toxoplasma Papillitis

Authors

  • AA Mas Putrawati Triningrat Ophthalmology Department, Faculty of Medicine, Udayana University, Sanglah Hospital, Denpasar, Bali, Indonesia
  • Ratna Sari Dewi Ophthalmology Department, Faculty of Medicine, Udayana University, Sanglah Hospital, Denpasar, Bali, Indonesia
  • Igam Juliari Ophthalmology Department, Faculty of Medicine, Udayana University, Sanglah Hospital, Denpasar, Bali, Indonesia
  • NK Niti Susila Ophthalmology Department, Faculty of Medicine, Udayana University, Sanglah Hospital, Denpasar, Bali, Indonesia
  • Ni Made Ayu Surasmiati Ophthalmology Department, Faculty of Medicine, Udayana University, Sanglah Hospital, Denpasar, Bali, Indonesia
  • I Ketut Agus Somia Internal Medicine Department, Faculty of Medicine, Udayana Unoversity, Sanglah Hospital, Denpasar, Bali, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2019.488

Keywords:

Toxoplasma Papillitis, HIV, Steroid

Abstract

BACKGROUND: Toxoplasmosis is a zoonotic disease caused by Toxoplasma gondii. Ocular manifestations are seen in both congenital and acquired toxoplasmosis. These can include focal inflammation within or around the optic nerve head (papillitis). Purpose of this study is evaluating the efficacy of systemic steroid in HIV patient with toxoplasma papillitis.
CASE PRESENTATION: We present a case report of a male, 46 years old with a decrease of visual acuity on the right eye for three weeks before admission to the hospital. An ophthalmology examination showed visual acuity of the right eye 1/60, mild dilatation of the pupil and posterior synechiae, vitreous was hazy, and fundus examination showed optic nerve head not well demarcated and hyperaemic with the good retina and macula reflex. Laboratory examination showed reactive anti-Toxoplasma immunoglobulin G. Patient had been treated with antiretroviral and anti-Toxoplasma drugs, then he was given steroid 250 mg intravenously four times per day for three days and tapering off orally. Visual acuity on the right eye improve from 1/60 became 6/60 after use of steroid on the third day.
DISCUSSION: Steroid can improve visual acuity for toxoplasma papillitis in this patient. But the long term and close follow up in steroid therapy is needed.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Miro JM, Murray HW, Katlama C. Toxoplasmosis. In: Dolin R, ed. AIDS Therapy. 3rd ed. Philadelphia, PA: Churchill Livingstone, 2008:659-681

Jones JL, Kruszon-Moran D, Sanders-Lewis K, Wilson M. Toxoplasma Gondii Infection in the United States. Am J Trop Med Hyg. 2007; 77(3):405-410. https://doi.org/10.4269/ajtmh.2007.77.405 PMid:17827351

Park YH, Nam HW. Clinical Feature and Treatment of Ocular Toxoplasmosis. Korean Journal of Parasitology. 2013; 51(4):393-399. https://doi.org/10.3347/kjp.2013.51.4.393 PMid:24039281 PMCid:PMC3770869

Jayawardene et al. Manifestation and Management of Ocular Toxoplasmosis. Indian Jr of Ophthalmol. 2008; 5(2):213-215 .

Luft BJ, Remington JS. Toxoplasmosis Encephalitis in AIDS. Clinical Infectious Disease. 1992; 15(2):211-222. https://doi.org/10.1093/clinids/15.2.211 PMid:1520757

Alipanahi R, Sayyahmelli S. Acute Papillitis in Young Female with Toxoplasmosis. Middle East African Journal Ophthalmology. 2011; 18(3):249-251. https://doi.org/10.4103/0974-9233.84060 PMid:21887084 PMCid:PMC3162741

Ahmed Irma, Everett A, Chang E, Luckie A. Ophthalmic Manifestation of HIV. University of California, San Fransisco, 2006:859-873.

Gritz David. Toxoplasmosis. Am J Trop Med Hyg. 2014; 80(2):401-409.

Harvey Uy. Toxoplasma Papillitis and Neuroretinitis. Philippine Journal of Ophthalmology. 2008; 30(1):48-53.

Myers TD, Smith JR, Wertheim MS, et al. Use Of Corticosteroid Sparing Systemic Immunosuppression for Treatment of Corticosteroid dependant Optic Neuritis not Associated with Demyelinating Disease. Br J Opthalmology. 2004; 17:3-8.

Gagliuso DJ, Teich SA, Friedman AH, Orellana J. Ocular Toxoplasmosis in AIDS Patients.Trans Am Opthalmol Soc. 1990; 88:63-86.

Holland GN. Ocular Toxoplasmosis in The Immunocompromised Host. Int Opthalmol. 1989; 13:399-402. https://doi.org/10.1007/BF02306488

American Academy of Ophthalmology Staff. Toxoplasma Retinochoroiditis. In: Intraocular Inflammation and Uveitis. Basic and clinical course. Section 9. San Fransisco:AAO, 2015-2016:308-309.

Jasper S, Satyanarayana S, et al. Corticosteroids for Ocular Toxoplasmosis. National of Health Institute Public. 2014; 4:2-16.

Gilbert RE, Harden M, Stanford MR. Antibiotics versus control fot Toxoplasma retinochoroiditis. Cochrane Database of Systematic Reviews. 2002; 1(10):218-226. https://doi.org/10.1002/14651858.CD002218

Rush R, Sheth S. Fulminant toxoplasmic retino-choroiditis following intravitreal triamcinolone administration. Indian journal of ophthalmology. 2012; 60(2):141-143. https://doi.org/10.4103/0301-4738.94059 PMid:22446913 PMCid:PMC3339077

Sabates R, Pruett RC, Brockhusrt RJ. Fulminant Ocular Toxoplasmosis.American Journal of Opthalmology. 1981; 92(4):497-503. https://doi.org/10.1016/0002-9394(81)90642-5

Aberdein J and Singer M. Clinical Review: A Systematic Review of Corticosteroid Use in Infections. Critical Care. 2005; 10:203-213. https://doi.org/10.1186/cc3904 PMid:16356204 PMCid:PMC1550829

Published

2019-06-17

How to Cite

1.
Triningrat AMP, Dewi RS, Juliari I, Susila NN, Surasmiati NMA, Somia IKA. Management of Systemic Steroid in HIV Patient with Toxoplasma Papillitis. Open Access Maced J Med Sci [Internet]. 2019 Jun. 17 [cited 2024 Apr. 18];7(11):1821-4. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2019.488

Issue

Section

C- Case Reports

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.